Skip to main
ALLO

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics is a clinical stage immuno-oncology company with a positive outlook from a financial analyst, driven by their promising pipeline and recent addition of a new cohort to the ALPHA3 study which aims to provide important context for MRD-negative patients. The bull case scenario values the company at $11 per share using a DCF-based valuation methodology and an 85% probability of approval for their LBCL treatment. However, potential risks include shorter-than-expected effectiveness, safety concerns, and manufacturing challenges.

Bears say

Allogene Therapeutics is facing significant obstacles in their development of allogeneic T cell product candidates, as evidenced by a recent real-world study highlighting the unmet need in LBCL and a low proportion of patients receiving CART therapy in the 2L and 3L settings. Additionally, while some data on their ALLO-329 program will be released in 4Q26, there is still a lack of clinical and translation updates on this program, indicating potential hurdles in its development. Lastly, the company's financials may also be a cause for concern, as they have a heavy reliance on partnerships for their key pipeline and are facing competition from next-generation CAR T therapies.

ALLO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 9 analysts, ALLO has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.